Keeping in view the company's commitment to innovate for life, the R&D team continuously strives to develop processes to produce the highest quality products using the state-of-the-art technologies in the field. Plasma derivatives are manufactured using an end-to-end advanced chromatography based processes as opposed to the older technology of Cohn’s ethanol based precipitation technique. Viral safety is ensured by the incorporation of multiple orthogonal viral inactivation and removal steps in the process. The plasma derivatives manufactured by Ichor conforms to the most stringent international standards for safety and efficacy of plasma derivatives.

Scientists at Ichor are actively engaged in a wide variety of projects ranging from development of new plasma products and new formulations to identifying new targets for therapeutic intervention.